The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
Conflict and Health 2015, 9:8 doi:10.1186/s13031-015-0035-8
The conditionality of this recommendation is largely driven by the current higher unit cost of pyrethroid-PBO ITNs compared
to pyrethroid-only LLINs and therefore the uncertainty of their cost-effectiveness. Furthermore, as PBO is less wash-resistant
than pyrethroids, its bioavailability declines ...faster over the three-year estimated life of an ITN; therefore, the added impact of
pyrethroid-PBO ITNs over that of pyrethroid-only LLINs may decline over time. The evidence comes from two sites in
eastern Africa with pyrethroid resistance and not from other geographies where transmission levels and vector characteristics
may vary. PBO acts by inhibiting certain metabolic enzymes, primarily oxidases, and so are likely to provide greater protection
than pyrethroid-only LLINs where mosquitoes display mono-oxygenase-based insecticide resistance mechanisms.
more
Information for policy-makers and planners on conducting deworming as part of an integrated
school health program
Prévalence du VIH au Bénin : résultats de l’EDSB-IV 2011-2012
Patient information on depression. English version. Also available in: Arabic, French, German, Russian, Turkish, Spanish. For other versions go to: http://www.patienten-information.de/kurzinformationen/psychische-erkrankungen/depression
MEDBOX Issue Brief No.17, 21 November 2021
Women's cancers have a significant impact on women's health worldwide. According to the World Health Organisation, nearly three million women are diagnosed with breast or cervical cancer every year. In this Issue Brief you will find more information.
Background paper prepared for the Education for All Global Monitoring Report 2012
Reports from Kenya, Sierra Leone, China and Sri Lanka
The Countdown country profile presents in one place the best and latest evidence to enable an assessment of a country’s progress in improving reproductive, maternal, newborn, and child health (RMNCH)
This policy brief is targeted at national governments, donors and regional and international actors to support Ebola-affected countries to transition from emergency response to recovery.
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.